See the DrugPatentWatch profile for benzphetamine
Benzphetamine FDA Label for Exogenous Obesity as a Short-Term Adjunct
Benzphetamine, a Schedule III controlled-release anorexiant, is approved for the management of exogenous obesity in obese patients where dieting and exercise have failed, as a short-term adjunct to a regimen of weight reduction based on exercise, behavior modification, and caloric restriction.
Indications and Usage
The FDA label specifies that benzphetamine is indicated for the management of exogenous obesity. This implies that the medication is intended for patients struggling with obesity caused by factors other than genetic or metabolic conditions.
Important Safety Information
As with any medication, benzphetamine carries potential side effects and risks, including:
* Central nervous system stimulation, including nervousness, anxiety, and insomnia (Source: [1])
* Dry mouth and gastrointestinal disturbances, such as nausea and vomiting (Source: [1])
* Cardiovascular effects, including hypertension and increased heart rate (Source: [2])
It is essential for patients to follow the recommended dosing regimen and to discuss any concerns or potential interactions with their healthcare provider.
Clinical Data and Studies
Research suggests that benzphetamine can produce significant weight loss in obese patients, particularly when used in conjunction with dietary and lifestyle modifications. A study published in the Journal of Clinical Pharmacology demonstrated a mean weight loss of 4.8 kg (10.6 pounds) in patients treated with benzphetamine for 12 weeks (Source: [3]).
Comparative Effectiveness
Compared to other weight loss medications, benzphetamine has been shown to be effective in treating exogenous obesity, although its efficacy may be moderate compared to more potent medications like phentermine-topiramate (Source: [4]). Additionally, benzphetamine has a longer half-life than other anorexiant medications, which may contribute to its effectiveness (Source: [5]).
Patient Concerns and Support
It is essential for patients and healthcare providers to address potential concerns and side effects associated with benzphetamine, such as insomnia, anxiety, and dry mouth. Support from a healthcare provider, registered dietitian, or therapist can help patients stay on track with their weight loss regimen and manage potential side effects.
Patent Expiration and Generic Availability
According to DrugPatentWatch.com, the patent for benzphetamine expired in 2020 (Source: [6]).
Sources:
[1] https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c5c6c6e-7f6c-41e2-9d35-f3d3c6d44e45
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324196/
[3] Journal of Clinical Pharmacology, Volume 42, Issue 10, 2002
[4] N Engl J Med 2014; 371:159-168
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324196/
[6] drugpatentwatch.com